Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 112

Similar articles for PubMed (Select 22343194)

1.

Influence of achieved low-density lipoprotein cholesterol level with atorvastatin therapy on stabilization of coronary plaques: sub-analysis of the TWINS study.

Okada K, Ueda Y, Takayama T, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Takazawa K, Nanto S, Saito S, Hirayama A, Kodama K.

Circ J. 2012;76(5):1197-202. Epub 2012 Feb 17.

2.

The difference between Asian and Western in the effect of LDL-C lowering therapy on coronary atherosclerotic plaque: a meta-analysis report.

Li YF, Feng QZ, Gao WQ, Zhang XJ, Huang Y, Chen YD.

BMC Cardiovasc Disord. 2015 Feb 14;15:6. doi: 10.1186/1471-2261-15-6.

3.

Effect of atorvastatin therapy on fibrous cap thickness in coronary atherosclerotic plaque as assessed by optical coherence tomography: the EASY-FIT study.

Komukai K, Kubo T, Kitabata H, Matsuo Y, Ozaki Y, Takarada S, Okumoto Y, Shiono Y, Orii M, Shimamura K, Ueno S, Yamano T, Tanimoto T, Ino Y, Yamaguchi T, Kumiko H, Tanaka A, Imanishi T, Akagi H, Akasaka T.

J Am Coll Cardiol. 2014 Dec 2;64(21):2207-17. doi: 10.1016/j.jacc.2014.08.045. Epub 2014 Nov 24.

PMID:
25456755
4.

Systematic study of the effects of lowering low-density lipoprotein-cholesterol on regression of coronary atherosclerotic plaques using intravascular ultrasound.

Gao WQ, Feng QZ, Li YF, Li YX, Huang Y, Chen YM, Yang B, Lu CY.

BMC Cardiovasc Disord. 2014 May 2;14:60. doi: 10.1186/1471-2261-14-60. Review.

5.

Risk markers for coronary plaque progression and destabilization beyond LDL-cholesterol in acute coronary syndrome.

Taguchi I, Koizumi S, Kageyama M, Nasuno T, Toyoda S, Abe S, Node K, Inoue T.

Int J Cardiol. 2014 May 1;173(2):329-31. doi: 10.1016/j.ijcard.2014.03.051. Epub 2014 Mar 15. No abstract available.

PMID:
24680249
6.

Post-marketing study of clinical experience of atorvastatin 80 mg vs 40 mg in Indian patients with acute coronary syndrome- a randomized, multi-centre study (CURE-ACS).

Kaul U, Varma J, Kahali D, Hiremath MS, Dani S, Dalal J, Ramchandran P, Rane R, Barkate H, Jindal C.

J Assoc Physicians India. 2013 Feb;61(2):97-101.

PMID:
24471247
7.

A predictor of atheroma progression in patients achieving very low levels of low-density lipoprotein cholesterol.

Nozue T, Yamamoto S, Tohyama S, Fukui K, Umezawa S, Onishi Y, Kunishima T, Hibi K, Terashima M, Michishita I.

Am J Cardiovasc Dis. 2013 Nov 1;3(4):255-63. eCollection 2013.

8.
9.

Effect of minocycline on carotid atherosclerotic plaques.

Gao J, Gao X, Pan S.

Neurol Res. 2013 Oct;35(8):844-50. doi: 10.1179/1743132813Y.0000000223. Epub 2013 May 14.

PMID:
23676309
10.
11.

Plaque stabilization by intensive LDL-cholesterol lowering therapy with atorvastatin is delayed in type 2 diabetic patients with coronary artery disease-Serial angioscopic and intravascular ultrasound analysis.

Takayama T, Hiro T, Ueda Y, Honye J, Komatsu S, Yamaguchi O, Li Y, Yajima J, Takazawa K, Nanto S, Saito S, Hirayama A, Kodama K.

J Cardiol. 2013 Jun;61(6):381-6. doi: 10.1016/j.jjcc.2013.01.010. Epub 2013 Mar 9.

12.

Localization of oxidized low-density lipoprotein and its relation to plaque morphology in human coronary artery.

Uchida Y, Maezawa Y, Uchida Y, Hiruta N, Shimoyama E, Kawai S.

PLoS One. 2013;8(2):e55188. doi: 10.1371/journal.pone.0055188. Epub 2013 Feb 5.

13.

Molecular imaging of low-density lipoprotein in human coronary plaques by color fluorescent angioscopy and microscopy.

Uchida Y, Maezawa Y, Uchida Y, Hiruta N, Shimoyama E.

PLoS One. 2012;7(11):e50678. doi: 10.1371/journal.pone.0050678. Epub 2012 Nov 28.

14.

Plaque regression measured by intravascular ultrasound and reduction of cardiovascular events: not yet the case, commentary on the study of D'Ascenzo et al.

Rocha VZ, Santos RD.

Atherosclerosis. 2013 Jan;226(1):45-6. doi: 10.1016/j.atherosclerosis.2012.10.066. Epub 2012 Nov 6. No abstract available.

PMID:
23177974
15.

Intensive-dose atorvastatin regimen halts progression of atherosclerotic plaques in new-onset unstable angina with borderline vulnerable plaque lesions.

Zhang X, Wang H, Liu S, Gong P, Lin J, Lu J, Qiu J, Lu X.

J Cardiovasc Pharmacol Ther. 2013 Mar;18(2):119-25. doi: 10.1177/1074248412465792. Epub 2012 Nov 8.

PMID:
23139359
16.

Effect of intensive atorvastatin therapy on coronary atherosclerosis progression, composition, arterial remodeling, and microvascular function.

Eshtehardi P, McDaniel MC, Dhawan SS, Binongo JN, Krishnan SK, Golub L, Corban MT, Raggi P, Quyyumi AA, Samady H.

J Invasive Cardiol. 2012 Oct;24(10):522-9.

17.

Serial change and its determinants of residual plaque characteristics under sirolimus-eluting stent: a coronary angioscopic study.

Kanai T, Hiro T, Takayama T, Watanabe Y, Fukamachi D, Kitano D, Kawano T, Hirayama A.

J Cardiol. 2012 Oct;60(4):270-6. doi: 10.1016/j.jjcc.2012.06.002. Epub 2012 Jul 21.

18.

Comparison of lipid control in patients with coronary versus peripheral artery disease following the first vascular intervention.

Pereg D, Neuman Y, Elis A, Minha S, Mosseri M, Segev D, Lishner M, Hermoni D.

Am J Cardiol. 2012 Nov 1;110(9):1266-9. doi: 10.1016/j.amjcard.2012.06.030. Epub 2012 Jul 21.

PMID:
22819425
19.

Malondialdehyde-modified low-density lipoprotein is a useful marker to identify patients with vulnerable plaque.

Tajika K, Okamatsu K, Takano M, Inami S, Yamamoto M, Murakami D, Kobayashi N, Ohba T, Hata N, Seino Y, Mizuno K.

Circ J. 2012;76(9):2211-7. Epub 2012 Jun 19.

20.

Association of the low-density lipoprotein cholesterol/high-density lipoprotein cholesterol ratio and body mass index with coronary plaque regression.

Tani S, Matsumoto M, Nakamura Y, Nagao K, Hirayama A.

Am J Cardiovasc Drugs. 2012 Aug 1;12(4):279-86. doi: 10.2165/11632520-000000000-00000.

PMID:
22747341
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk